| Heading: |
Prostate Cancer: Hormone Treatments |
| Question ID: |
1786973 |
| UIN: |
40092 |
| House: |
Commons |
| Date tabled: |
2025-03-20 |
| Asking Member ID: |
5336 |
| Asking Member display name: |
Helen Maguire
|
| Asking Member handle: |
helenemaguire
|
| Asking Member Twitter reference: |
@helenemaguire
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the Institute of Cancer Research's report entitled Cost-utility analysis of adding abiraterone acetate plus prednisone/ |
| Is named day: |
true |
| Date of holding answer: |
|
| Date answered: |
2025-03-25 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Abiraterone has a United Kingdom marketing authorisation for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated, and for castration-resistant metastatic prostate cancer previously treated with a docetaxel-contain... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |